Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results

Rhea-AI Summary

Bausch + Lomb, a global eye health company, announced the results of its 2024 annual shareholder meeting held on May 29, 2024. All 10 nominated directors were elected. Key votes included Nathalie Bernier, Gary Hu, Brett Icahn, Sarah B. Kavanagh, Karen L. Ling, John A. Paulson, Russel C. Robertson, Thomas W. Ross Sr., Brenton L. Saunders, and Andrew C. von Eschenbach.

Shareholders approved executive compensation in a non-binding advisory vote and an amendment to the 2022 Omnibus Incentive Plan, increasing the number of shares authorized for issuance. PricewaterhouseCoopers LLP was appointed as the independent registered public accounting firm until the 2025 annual meeting. The final vote results will be filed with the SEC on Form 8-K and will be available on the company's SEDAR+ profile and website.

Positive

• All 10 nominated directors were successfully elected.
• Shareholders approved the executive compensation in a non-binding advisory vote.
• An amendment to the 2022 Omnibus Incentive Plan was approved, increasing the number of shares authorized for issuance.
• PricewaterhouseCoopers LLP was appointed as the independent registered public accounting firm until the 2025 annual meeting.

Negative

• The press release does not provide detailed financial performance or projections, which may leave investors wanting more substantial business updates.

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2024 annual meeting of shareholders (the “Annual Meeting”) held on May 29, 2024. The detailed results of the vote for the election of directors are set out below:

Name	For	Against	Broker Non-Votes
Nathalie Bernier	344,550,519	28,790	3,089,749
Gary Hu	344,514,922	64,387	3,089,749
Brett Icahn	344,321,103	258,206	3,089,749
Sarah B. Kavanagh	343,504,035	1,075,274	3,089,749
Karen L. Ling	344,545,858	33,451	3,089,749
John A. Paulson	344,406,744	172,565	3,089,749
Russel C. Robertson	344,472,819	106,490	3,089,749
Thomas W. Ross, Sr.	344,356,329	222,980	3,089,749
Brenton L. Saunders	344,497,635	81,674	3,089,749
Andrew C. von Eschenbach, M.D.	344,353,602	225,707	3,089,749

At the Annual Meeting, shareholders also approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers, approved an amendment and restatement of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the “Plan”) to increase the number of common shares authorized for issuance thereunder, and appointed PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm until the close of the Company's 2025 annual meeting of shareholders.

For the purposes of Toronto Stock Exchange (“TSX”) approval with respect to the Plan, the Company relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible inter-listed issuers on a recognized exchange, such as the NYSE.

The final vote tabulation on all matters voted on at the Annual Meeting will be filed with the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile and on the Company’s website at www.bausch.com.

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529658656/en/

Media Contact:

Chris Clark

chris.clark@bausch.com

(848) 360-1100

Investor Contact:

George Gadkowski

george.gadkowski@bausch.com

(877) 354-3705 (toll free)

(908) 927-0735

Source: Bausch + Lomb Corporation

FAQ

What were the results of Bausch + Lomb's 2024 annual shareholder meeting?

All 10 nominated directors were elected, executive compensation was approved, and an amendment to the Omnibus Incentive Plan was passed. PricewaterhouseCoopers LLP was appointed as the independent registered public accounting firm until 2025.

When was Bausch + Lomb's 2024 annual shareholder meeting held?

The 2024 annual shareholder meeting was held on May 29, 2024.

Who were the directors elected at Bausch + Lomb's 2024 annual shareholder meeting?

The elected directors include Nathalie Bernier, Gary Hu, Brett Icahn, Sarah B. Kavanagh, Karen L. Ling, John A. Paulson, Russel C. Robertson, Thomas W. Ross Sr., Brenton L. Saunders, and Andrew C. von Eschenbach.

What is the stock symbol for Bausch + Lomb?

The stock symbol for Bausch + Lomb is BLCO.

Who was appointed as the independent registered public accounting firm for Bausch + Lomb until 2025?

PricewaterhouseCoopers LLP was appointed as the independent registered public accounting firm until 2025.

Did Bausch + Lomb shareholders approve executive compensation at the 2024 meeting?

Yes, shareholders approved the executive compensation in a non-binding advisory vote.

Was an amendment to Bausch + Lomb's Omnibus Incentive Plan approved?

Yes, shareholders approved the amendment to increase the number of shares authorized for issuance under the 2022 Omnibus Incentive Plan.